Semaglutide 3 mg/ml

DRUG2 trials

Sponsors

Novo Nordisk A/S, Signe Torekov

Conditions

Non-alcoholic SteatohepatitisObesity, Adolescent

Phase 2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

CompletedNCT05016882

Novo Nordisk A/SNon-alcoholic Steatohepatitis

Start: 2021-08-31End: 2025-03-14Updated: 2025-11-19

Phase 4

Young Adults With Early-onset Obesity Treated With Semaglutide

RecruitingNCT05574439

Signe TorekovObesity, Adolescent

Start: 2022-06-01End: 2026-04-30Target: 180Updated: 2025-12-18

Related Papers

Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial

BMJ Open2024-11-012 citations

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations